Status:

COMPLETED

Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain

Lead Sponsor:

SGX Procura LLC

Conditions:

Upper Limb

Pain

Eligibility:

All Genders

18+ years

Brief Summary

This is a post-market, open-label, prospective, multi-center, observational study evaluating upper limb pain relief with the DTM™ SCS programming approach. Data at follow-up visits will be compared t...

Detailed Description

This is a post-market, open-label, prospective, multi-center, observational study evaluating upper limb pain relief with the DTM™ SCS programming approach. Data at follow-up visits will be compared t...

Eligibility Criteria

Inclusion

  • A subject must MEET ALL of the following inclusion criteria:
  • Be diagnosed with chronic, intractable pain of the upper limb related to the cervical spine and/or neuropathic arm pain.
  • Be a candidate for SCS system (trial and implant) per labeled indication (upper limb pain due to one of the conditions listed in indications statement)
  • Considering daily activity and rest, has average upper limb pain intensity of ≥ 5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment
  • Be willing and capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided.
  • Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand and sign the written inform consent.
  • Be 18 years of age or older at the time of enrollment
  • Be on a stable pain medication regime, as determined by the study investigator, for at least 30 days prior to enrolling in this study
  • Be willing and able to comply with study -related requirements, procedures, and visits, including not increasing pain meds through the three month visit
  • Has adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator

Exclusion

  • A subject must NOT MEET ANY of the following exclusion criteria:
  • Has a medical, anatomical, and/or psychosocial condition that is contraindicated for commercially available IntellisTM SCS systems as determined by the Investigator
  • Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator
  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the study manager or designee)
  • Has an existing active implanted device such as a pacemaker, another SCS unit, peripheral nerve stimulator, and/or drug delivery pump.
  • Has pain in other area(s) and/or medical condition requiring the regular use of significant pain medications that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study endpoints, as determined by the Investigator
  • Has significant cervical stenosis, as determined by the Investigator
  • Has facet spondylosis, as determined by the Investigator
  • Has mechanical spine instability, as determined by the Investigator
  • Has undergone, within 30 days prior to enrollment, an interventional procedure and/or surgery to treat upper limb pain, which is providing significant pain relief
  • Has unresolved major issues of secondary gain (e.g., social, financial, legal, such as worker compensation matters)
  • Be pregnant as determined by urine testing unless female subject is surgically sterile or post-menopausal. If female, sexually active, and childbearing age, subject must be willing to use a reliable form of birth control.
  • Have evidence of an active disruptive psychological or psychiatric disorder as determined by a psychologist
  • Have a current diagnosis of a progressive neurological disease as determined by the Investigator
  • Have a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus
  • Have a condition that the Investigator determines would significantly increase perioperative risk
  • Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) of the cervical spine
  • Have metastatic malignant disease or active local malignant disease
  • Have a life expectancy of less than 1 year
  • Have an active systemic or local infection
  • Have within 6 months of enrollment a significant untreated addiction to dependency producing medications or have been a substance abuser (including alcohol and illicit drugs)

Key Trial Info

Start Date :

September 8 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 9 2023

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT04466111

Start Date

September 8 2020

End Date

March 9 2023

Last Update

August 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SGX Medical

Bloomington, Illinois, United States, 61704